المؤلفون: Fucà G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cohen R; Sorbonne Université, Department of Medical Oncology, Hôpital Saint-Antoine, AP-HP and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France., Lonardi S; Medical Oncology 3 and Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy., Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Elez ME; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain., Fakih M; Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Chao J; Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Klempner SJ; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Emmett M; Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Jayachandran P; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Bergamo F; Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy., García MD; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain., Mazzoli G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Provenzano L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Colle R; Sorbonne Université, Department of Medical Oncology, Hôpital Saint-Antoine, AP-HP and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France., Svrcek M; Sorbonne Université, Department of Pathology, Hôpital Saint-Antoine, AP-HP, and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France., Ambrosini M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Randon G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Shah AT; Baylor College of Medicine, Houston, Texas, USA., Salati M; Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, PhD Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy., Fenocchio E; Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy., Salvatore L; Department of Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Chida K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kawazoe A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Conca V; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Curigliano G; European Institute of Oncology (IEO), IRCCS, Milan, Italy.; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy., Corti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Overman M; Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Andre T; Sorbonne Université, Department of Medical Oncology, Hôpital Saint-Antoine, AP-HP and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy filippo.pietrantonio@istitutotumori.mi.it.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Feb; Vol. 10 (2).

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Ascites/*etiology , Colorectal Neoplasms/*complications , Colorectal Neoplasms/*drug therapy , Immune Checkpoint Inhibitors/*adverse effects , Stomach Neoplasms/*complications , Stomach Neoplasms/*drug therapy, Aged ; Ascites/pathology ; Colorectal Neoplasms/mortality ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Male ; Microsatellite Instability ; Neoplasm Metastasis ; Retrospective Studies ; Stomach Neoplasms/mortality ; Survival Analysis

المؤلفون: Chida K; National Cancer Center Hospital East, Kashiwa, Chiba, Japan.; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Kawazoe A; National Cancer Center Hospital East, Kashiwa, Chiba, Japan. akawazoe@east.ncc.go.jp., Kawazu M; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan., Suzuki T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.; General Medicinal Education and Research Center, Teikyo University, Tokyo, Japan., Nakamura Y; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Nakatsura T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan., Kuwata T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan., Ueno T; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan., Kuboki Y; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Kotani D; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Kojima T; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Taniguchi H; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Mano H; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan., Ikeda M; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Shitara K; National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Endo I; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Yoshino T; National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 01; Vol. 27 (13), pp. 3714-3724. Date of Electronic Publication: 2021 Apr 29.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Microsatellite Instability* , Mutation*, Gastrointestinal Neoplasms/*drug therapy , Gastrointestinal Neoplasms/*genetics , Immune Checkpoint Inhibitors/*therapeutic use , PTEN Phosphohydrolase/*genetics, Adult ; Aged ; Aged, 80 and over ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Exome Sequencing

المؤلفون: Wainberg ZA; Department of the Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California. zwainberg@mednet.ucla.edu., Fuchs CS; Department of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut., Tabernero J; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain., Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Van Cutsem E; University Hospitals and KU Leuven, Leuven, Belgium., Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea (South)., Chung HC; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea (South)., Yamaguchi K; Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Varga E; Department of Oncology, Debreceni Egyetem Klinikai Központ, Debrecen, Hungary., Chen JS; Department of Hematology, Oncology, Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan., Hochhauser D; Department of Medical Oncology, UCL Cancer Institute, London, United Kingdom., Thuss-Patience P; Department of Hematology, Oncology, and Tumor Immunology, Charité-University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany., Al-Batran SE; Deparment of Tumor Diseases, Institut für Klinisch-Onkologische, Frankfurt, Germany., Garrido M; Department of Hematology and Medical Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile., Kher U; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Shih CS; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Shah S; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Bhagia P; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, New Jersey., Chao J; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 01; Vol. 27 (7), pp. 1923-1931. Date of Electronic Publication: 2021 Jan 14.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Esophagogastric Junction*, Antibodies, Monoclonal, Humanized/*therapeutic use , Esophageal Neoplasms/*drug therapy , Immune Checkpoint Inhibitors/*therapeutic use , Stomach Neoplasms/*drug therapy, Adult ; Aged ; Esophageal Neoplasms/mortality ; Female ; Humans ; Male ; Middle Aged ; Stomach Neoplasms/mortality

المؤلفون: Kawazoe A; Department of Gastrointestinal Medical oncology, National Cancer Center Hospital East, Chiba, Japan., Shitara K; Department of Gastrointestinal Medical oncology, National Cancer Center Hospital East, Chiba, Japan., Boku N; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo., Yoshikawa T; Department of Gastric Surgery, National Cancer Center Hospital, Tokyo., Terashima M; Division of Gastric Surgery, Shizuoka Cancer Center, Nagaizumi.

المصدر: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Jan 01; Vol. 51 (1), pp. 20-27.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN: 1465-3621 (Electronic) Linking ISSN: 03682811 NLM ISO Abbreviation: Jpn J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Immune Checkpoint Inhibitors/*therapeutic use , Stomach Neoplasms/*drug therapy, Antibodies, Monoclonal, Humanized/therapeutic use ; Clinical Trials as Topic ; Combined Modality Therapy ; Humans ; Immunotherapy ; Microsatellite Instability ; Nivolumab/therapeutic use ; Stomach Neoplasms/genetics

المؤلفون: Kumagai S; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Togashi Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Kamada T; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Sugiyama E; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Nishinakamura H; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Takeuchi Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Vitaly K; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Itahashi K; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Maeda Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Matsui S; Department of Biostatics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Shibahara T; Research and Development Group, Hitachi Ltd., Tokyo, Japan., Yamashita Y; Research and Development Group, Hitachi Ltd., Tokyo, Japan., Irie T; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Tsuge A; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Fukuoka S; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan., Kawazoe A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Udagawa H; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan., Kirita K; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan., Aokage K; Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan., Ishii G; Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan., Kuwata T; Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan., Nakama K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan., Kawazu M; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan., Ueno T; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan., Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan., Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan., Tsuboi M; Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan., Mano H; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan., Doi T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Nishikawa H; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan. hnishika@ncc.go.jp.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. hnishika@ncc.go.jp.

المصدر: Nature immunology [Nat Immunol] 2020 Nov; Vol. 21 (11), pp. 1346-1358. Date of Electronic Publication: 2020 Aug 31.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Gene Expression Regulation/*drug effects , Immune Checkpoint Inhibitors/*pharmacology , Programmed Cell Death 1 Receptor/*antagonists & inhibitors , Programmed Cell Death 1 Receptor/*genetics , T-Lymphocytes, Regulatory/*immunology , T-Lymphocytes, Regulatory/*metabolism, Antigens/chemistry ; Antigens/immunology ; Biomarkers, Tumor ; CD28 Antigens/metabolism ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunomodulation ; Lymphocyte Activation/immunology ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Neoplasms/drug therapy ; Neoplasms/etiology ; Neoplasms/metabolism ; Neoplasms/mortality ; Peptides/chemistry ; Peptides/immunology ; Prognosis ; Programmed Cell Death 1 Receptor/metabolism ; Reactive Oxygen Species/metabolism ; Receptors, Antigen, T-Cell/metabolism ; Signal Transduction ; T-Lymphocytes, Regulatory/drug effects ; Treatment Outcome ; Tumor Microenvironment/immunology

المؤلفون: Sasaki A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Courses of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan., Nakamura Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Togashi Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Centre, National Cancer Center Hospital East, Kashiwa, Japan., Kuno H; Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan., Hojo H; Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan., Kageyama S; Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan., Nakamura N; Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan., Takashima K; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan., Kadota T; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan., Yoda Y; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan., Mishima S; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Sawada K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Kotani D; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Kawazoe A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Kuboki Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Taniguchi H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Kojima T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Doi T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Yano T; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan., Kobayashi T; Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan., Akimoto T; Courses of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan., Nishikawa H; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Centre, National Cancer Center Hospital East, Kashiwa, Japan., Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. kshitara@east.ncc.go.jp.

المصدر: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2020 Sep; Vol. 23 (5), pp. 893-903. Date of Electronic Publication: 2020 Mar 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3305 (Electronic) Linking ISSN: 14363291 NLM ISO Abbreviation: Gastric Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Adenocarcinoma/*secondary , Immune Checkpoint Inhibitors/*therapeutic use , Lymphocytes, Tumor-Infiltrating/*immunology , Programmed Cell Death 1 Receptor/*antagonists & inhibitors , Radiation Tolerance/*drug effects , Radiotherapy/*methods , Stomach Neoplasms/*pathology, Adenocarcinoma/drug therapy ; Adenocarcinoma/radiotherapy ; Aged ; CD8-Positive T-Lymphocytes/immunology ; Female ; Follow-Up Studies ; Humans ; Male ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/radiotherapy ; T-Lymphocytes, Regulatory/immunology ; Tumor Microenvironment/immunology

المؤلفون: Kubota Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.; Courses of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan., Kawazoe A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Sasaki A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Mishima S; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Sawada K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Nakamura Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Kotani D; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Kuboki Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Taniguchi H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Kojima T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Doi T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Ishii G; Courses of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan., Kuwata T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan., Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan. kshitara@east.ncc.go.jp.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jul 15; Vol. 26 (14), pp. 3784-3790. Date of Electronic Publication: 2020 Mar 10.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Epstein-Barr Virus Infections/*drug therapy , Gastric Mucosa/*pathology , Immune Checkpoint Inhibitors/*pharmacology , Stomach Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; DNA Mismatch Repair ; Drug Resistance, Neoplasm ; Epstein-Barr Virus Infections/genetics ; Epstein-Barr Virus Infections/mortality ; Epstein-Barr Virus Infections/virology ; Female ; Follow-Up Studies ; Gastric Mucosa/virology ; Herpesvirus 4, Human/isolation & purification ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Male ; Middle Aged ; Progression-Free Survival ; Receptor, ErbB-2/analysis ; Receptor, ErbB-2/metabolism ; Retrospective Studies ; Stomach Neoplasms/genetics ; Stomach Neoplasms/mortality ; Stomach Neoplasms/virology ; Young Adult

المؤلفون: Kumagai S; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Togashi Y; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan. Electronic address: ytogashi1584@gmail.com., Sakai C; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan., Kawazoe A; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Kawazu M; Division of Cellular Signaling, Group for Cancer Development and Progression, National Cancer Center Research Institute, Tokyo, Japan., Ueno T; Division of Cellular Signaling, Group for Cancer Development and Progression, National Cancer Center Research Institute, Tokyo, Japan., Sato E; Department of Pathology, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan., Kuwata T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan., Kinoshita T; Department of Gastric Surgery, National Cancer Center Hospital East, Chiba, Japan., Yamamoto M; Division of Physiological Pathology, Department of Applied Science, School of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, Tokyo, Japan., Nomura S; Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tsukamoto T; Department of Pathology, Graduate School of Medicine, Fujita Health University, Aichi, Japan., Mano H; Division of Cellular Signaling, Group for Cancer Development and Progression, National Cancer Center Research Institute, Tokyo, Japan., Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Nishikawa H; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: hnishika@ncc.go.jp.

المصدر: Immunity [Immunity] 2020 Jul 14; Vol. 53 (1), pp. 187-203.e8. Date of Electronic Publication: 2020 Jul 07.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 9432918 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4180 (Electronic) Linking ISSN: 10747613 NLM ISO Abbreviation: Immunity Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes/*immunology , Immune Checkpoint Inhibitors/*pharmacology , Stomach Neoplasms/*genetics , T-Lymphocytes, Regulatory/*metabolism , rhoA GTP-Binding Protein/*genetics, Animals ; CD4 Lymphocyte Count ; CD8-Positive T-Lymphocytes/metabolism ; Cell Line, Tumor ; Chemokine CXCL10/biosynthesis ; Chemokine CXCL11/biosynthesis ; Fatty Acids, Nonesterified/biosynthesis ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Nude ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphoinositide-3 Kinase Inhibitors/pharmacology ; Programmed Cell Death 1 Receptor/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction/immunology ; Stomach Neoplasms/immunology ; Stomach Neoplasms/pathology ; T-Lymphocytes, Regulatory/immunology ; TOR Serine-Threonine Kinases/metabolism ; Tumor Microenvironment/immunology

المؤلفون: Kubota Y, Aoki Y, Kawazoe A, Shitara K

المصدر: Cancer Management and Research, Vol Volume 14, Pp 3083-3094 (2022)

مصطلحات موضوعية: immune checkpoint inhibitors, chemotherapy, programmed cell death-1, human epidermal growth factor receptor 2, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/role-of-nivolumab-in-the-management-of-first-line-unresectable-advance-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/377927e4c6fa4fdf97a6609426c0665b

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.